Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...
Treatment modalities for advanced solid pseudopapillary tumor of the pancreas. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback